

RESEARCH

Open Access



Evaluation of the effect of donor weight on adipose stromal/stem cell characteristics by using weight-discordant monozygotic twin pairs

Miia Juntunen^{1,2*} , Sini Heinonen^{3,4}, Heini Huhtala⁵, Aila Rissanen³, Jaakko Kaprio⁶, Kirsi Kuismanen^{1,7}, Kirsi H. Pietiläinen^{3,4}, Susanna Miettinen^{1,2†} and Mimmi Patrikoski^{1,2,3†}

Abstract

Background: Adipose stromal/stem cells (ASCs) are promising candidates for future clinical applications. ASCs have regenerative capacity, low immunogenicity, and immunomodulatory ability. The success of future cell-based therapies depends on the appropriate selection of donors. Several factors, including age, sex, and body mass index (BMI), may influence ASC characteristics. Our aim was to investigate the effect of acquired weight on ASC characteristics under the same genetic background using ASCs derived from monozygotic (MZ) twin pairs.

Methods: ASCs were isolated from subcutaneous adipose tissue from five weight-discordant (WD, within-pair difference in BMI > 3 kg/m²) MZ twin pairs, with measured BMI and metabolic status. The ASC immunophenotype, proliferation and osteogenic and adipogenic differentiation capacity were studied. ASC immunogenicity, immunosuppression capacity and the expression of inflammation markers were investigated. ASC angiogenic potential was assessed in cocultures with endothelial cells.

Results: ASCs showed low immunogenicity, proliferation, and osteogenic differentiation capacity independent of weight among all donors. ASCs showed a mesenchymal stem cell-like immunophenotype; however, the expression of CD146 was significantly higher in leaner WD twins than in heavier cotwins. ASCs from heavier twins from WD pairs showed significantly greater adipogenic differentiation capacity and higher expression of *TNF* and lower angiogenic potential compared with their leaner cotwins. ASCs showed immunosuppressive capacity in direct cocultures; however, heavier WD twins showed stronger immunosuppressive capacity than leaner cotwins.

Conclusions: Our genetically matched data suggest that a higher weight of the donor may have some effect on ASC characteristics, especially on angiogenic and adipogenic potential, which should be considered when ASCs are used clinically.

Keywords: Adipose stem cells, Cell surface markers, Differentiation, Immunogenicity, Immunosuppression, Proliferation

Introduction

Adipose stromal/stem cells (ASCs) are multipotent mesenchymal stromal/stem cells (MSCs) that represent a promising tool for tissue regeneration applications as well as for cell-based treatment of inflammatory and

*Correspondence: miia.juntunen@tuni.fi

†Susanna Miettinen and Mimmi Patrikoski have contributed equally to this work

¹ Adult Stem Cell Group, Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, 33014 Tampere, Finland
Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

autoimmune conditions [1]. The International Society for Cellular Therapy (ISCT) has stated minimal definitions for MSCs [2]. MSCs are heterogeneous, plastic adherent cells, which express CD90, CD73, and CD105 and lack the expression of CD45, CD34, CD14 or CD11b, CD79 α or CD19, and HLA-DR and differentiate into adipogenic, osteogenic, and chondrogenic lineages in vitro [2]. The success of future cell-based therapies may depend on the appropriate selection of donors. Several factors of the donor, such as age [3–5] and sex [6], have been suggested to affect ASC characteristics. For instance, the osteogenic differentiation [4–6] and proliferation [7] capacity of ASCs have been shown to differ according to donor properties. Moreover, culturing conditions may influence ASC characteristics [8], and the passaging of cells may alter the ASC immunophenotype as the cell population becomes more homogenous [9, 10].

The World Health Organization estimated in 2016 that more than 1.9 billion adults are overweight (39%), of which 650 million are obese (13%) [11]. Excess weight gain leads to overweight and obesity, which causes inflammation in adipose tissue (AT). Obesity changes the metabolic and endocrine functions of AT, leading to various metabolic diseases, such as insulin resistance and type II diabetes [12], cardiovascular diseases, musculoskeletal disorders and some cancers [13]. The influence of obesity has become an interesting question for cell therapy, since in recent studies, it has been shown that obesity and chronic inflammation may affect ASC characteristics and functionality [14, 15].

ASCs isolated from donors with obesity (obASCs) may have altered immunophenotypes [16, 17]. Furthermore, the proliferation capacity of obASCs may be either increased [16, 18] or decreased compared with that of ASCs isolated from lean donors (lnASCs) depending on the study [17, 19–22], and in obASCs, senescence-associated gene expressions may be upregulated [22]. Most of the studies have shown a decreased differentiation capacity of obASCs. The osteogenic capacity of obASCs has been shown to decrease compared with lnASCs both in vivo [23] and in vitro [17, 19, 23], and adipogenic differentiation capacity has been shown to decrease in vitro [16, 17, 21, 24, 25]. However, regarding both osteogenic [26, 27] and adipogenic [18, 19, 26] differentiations, opposing results exist in which the differentiation capacity of obASCs has either increased [18, 26] or has not been affected [19, 27] compared to lean donors. Moreover, obASCs may have a reduced capacity for immunosuppression compared with lnASCs [28, 29]. These studies have brought into question whether obASCs should be used in tissue engineering applications [23] or as a cell-based therapy for inflammatory diseases [29].

Since the previous results are partly contradictory, the effect of increased weight on ASCs should be investigated in more detail taking the genetics of the donor into account. Our present study aims to clarify whether controlling for genetic background affects the association of weight with ASC characteristics. We used rare donor material of weight-discordant (WD) monozygotic (MZ) adult twin pairs [30]. The aim of the current study was to investigate the effect of intrapair differences in weight on basic ASC characteristics such as the proliferation and differentiation capacity, immunological characteristics, and ASC angiogenic potential while controlling for genetic variation between the lean and heavy groups.

Materials and methods

Weight-discordant MZ twin donors

This study included five WD (within-pair difference in body mass index (BMI) > 3 kg/m²) MZ twin pairs (age = 33.5–34.1 years at time of the study, males $n=6$, females $n=4$), from two population-based large twin cohorts, namely FinnTwin16 and FinnTwin12 ($n=5417$ pairs). The twin pairs have previously been part of a larger metabolic study [30]. MZ twins were categorized into two groups: leaner cotwins ($n=5$, mean BMI 26.4 ± 7.7 kg/m²) and heavier cotwins ($n=5$, mean BMI 31.6 ± 7.9 kg/m²; Table 1). The term cotwin is used when referring to a birth partner of a MZ twin. Written informed consent was obtained from all participants. The study was conducted in accordance with the Ethics Committee of Hospital District of Helsinki and Uusimaa, Helsinki, Finland (270/13/03/01/2008).

Measurements of biochemical variables

Weight and height were measured after a 12-h overnight fast while barefoot and in light clothing to calculate BMI. Fasting blood samples were taken from all donors to measure clinical parameters as follows. The concentrations of serum high-sensitivity C reactive protein (hs-CRP) were measured by a particle-enhanced immunoturbidimetric assay (Cobas CRP [latex] HS, Roche Diagnostics, Mannheim, Germany) on a modular automatic analyzer (Hitachi, Ltd., Tokyo, Japan). Plasma leptin and adiponectin were measured by enzyme-linked immunosorbent assays (ELISA; DuoSet ELISA, R&D Systems Europe, Abingdon, UK), and plasma total and high-density lipoprotein (HDL) cholesterol and triglyceride levels were measured by enzymatic methods (Roche Diagnostics Hitachi, Hitachi Ltd, Tokyo, Japan). Low-density lipoprotein (LDL) cholesterol was calculated by the Friedewald formula. A 75-g oral glucose tolerance test was performed after participants had fasted for 12-h overnight to calculate the insulin resistance index

Table 1 Clinical characteristics of the MZ twins

Variable	Weight-discordant pairs (Δ BMI > 3 kg/m ²)						p Value
	Leaner cotwin			Heavier cotwin			
	Median	Min	Max	Median	Min	Max	
BMI	23.3	21.5	39.9	26.8	25.8	44.2	0.043
Cholesterol (mmol/l)	3.9	3.0	4.7	5.0	3.0	6.9	0.276
Triglycerides (mmol/l)	0.6	0.5	0.8	1.4	0.5	2.7	0.225
HDL (mmol/l)	1.7	1.3	2.1	1.3	0.5	2.2	0.138
LDL (mmol/l)	2.0	1.6	3.0	3.4	1.6	4.5	0.080
hs-CRP (mg/l)	0.4	0.2	3.9	0.8	0.2	7.0	0.225
HOMA-IR	0.8	0.3	1.0	1.8	0.6	2.7	0.138
Plasma leptin (ng/ml)	10.0	0.7	77.6	22.1	5.2	55.7	0.500
Plasma adiponectin (ng/ml)	5050	3700	7710	4030	1310	4930	0.043

Wilcoxon's signed-rank test was used to compare the values of the leaner vs heavier cotwin. A *p* value less than 0.05 was considered significant (shown in bold). HDL = high-density lipoprotein, LDL = low-density lipoprotein, hs-CRP = high-sensitivity C reactive protein, HOMA-IR = insulin resistance index

(HOMA-IR). Zygosity was confirmed by genotyping 10 informative genetic markers [31].

ASC isolation and culture

Subcutaneous AT was biopsied from both twins in MZ twin pairs, and ASCs were isolated from AT and maintained as previously described [32]. ASCs were cultured in DMEM/F12 (1:1; Thermo Fisher Scientific Inc., Carlsbad, CA) supplemented with 5% human serum (HS; Paa Laboratories/BioWest) or 5% pooled human platelet lysate (HPL; Stemulate™; Cook General BioTechnology, Indianapolis, IN), 1% antibiotics (100 U/ml penicillin and 0.1 mg/ml streptomycin; Thermo Fisher Scientific Inc.), and 1% L-glutamine (GlutaMAX-100; Thermo Fisher Scientific Inc.; see Additional file 1: Table 1). Differentiation of ASCs and angiogenesis assays was assessed in HS medium and other analyses in HPL medium. The medium was changed twice a week, and the cells were divided upon reaching confluency. Cells were detached using TrypLE Select (Thermo Fisher Scientific Inc.).

Immunophenotype

The phenotype of ASCs was assessed with flow cytometry (BD FACSAria™ Fusion Cell Sorter; BD Biosciences) at passage 5. Monoclonal antibodies against CD markers (see Additional file 1: Table 2) CD19-phycoerythrin-cyanine (PE-Cy7), CD14- PE-CF594, CD34-PE-CF594, CD45RO- allophycocyanin (APC), CD54-brilliant violet 711 (BV711), CD73-PE-Cy7, CD90-APC, CD146-PE, HLA-DR-BV421 (BD Biosciences), CD105-fluorescein isothiocyanate (FITC), and HLA-ABC-PE (ImmunoTools GmbH, Friesoythe, Germany) were used. Multicolor staining was used to assess the immunophenotype of ASCs. Ten thousand cells were analyzed, and unstained

cells were used to adjust the cytometer. Compensation for all the antibodies was performed using Compensation Plus beads (BD Biosciences).

Proliferation

The proliferation of ASCs was assessed with the Cell Counting Kit-8 assay (CCK-8; Dojindo Laboratories, Japan) as previously described [33] at passage 4 or 5. Briefly, cells were seeded in 48-well plates (Nunc, Thermo Fisher Scientific Inc.) at a density of 260 cells/cm², and proliferation was measured at 4, 7, and 11 days in HPL medium. Culture medium was discarded, wells were rinsed with Dulbecco's phosphate-buffered saline (DPBS; Lonza, BioWhittaker, Verviers, Belgium), and proliferation was measured using a microplate reader (Victor 1429 Multilabel Counter, Wallac, Turku, Finland) at 450 nm after incubating cells for 3 h in DPBS and CCK-8 reagent 10:1 at 37 °C in a CO₂ incubator (Heracell).

Osteogenic differentiation, mineralization, and alkaline phosphatase activity

For osteogenic differentiation capacity studies, ASCs were seeded in 24-well plates (Corning® CELLBIND® Corning Inc., Corning, NY, USA) at a density of 260 cells/cm² at passage 3 or 4. ASCs were cultured in osteogenic medium (OM; see Additional file 1: Table 1) for 21 days for Alizarin red (AR) staining, and quantification (QAR) was performed as previously described [34]. To study the early osteogenic differentiation of ASCs, ASCs were cultured in OM for 14 days. Alkaline phosphatase (ALP) activity measurements were performed, and the results were normalized to the DNA amount from CyQUANT analysis from the same cell lysates as previously described [34]. DNA amount measurement was conducted with

a CyQUANT™ cell proliferation assay kit (Molecular Probes, Invitrogen™, Paisley, UK) according to the manufacturer's protocol.

Adipogenic differentiation and quantification of lipid formation

For adipogenic differentiation capacity studies, ASCs were seeded in 24-well plates (Corning® CELLBIND®) at a density of 260 cells/cm² at passage 3 or 4. ASCs were cultured in adipogenic medium (AM; see Additional file 1: Table 1) for 21 days, and Oil Red O staining (ORO) was performed as previously described [35]. Cells were photographed with a fluorescence microscope (Nikon Olympus), and lipid formation was analyzed using quantified ORO (QORO) and DAPI images as previously described [35] using CellProfiler software (version 2.1.1, 64-bit Windows). Lipid formation was evaluated by applying a 10-μm-diameter threshold to identify large lipid droplet (LD) clusters.

qRT-PCR for osteogenic, adipogenic, and inflammatory markers

The relative expression of the osteogenic genes *Runt-related transcription factor 2 (RUNX2)* and *ALP* and the adipogenic genes *peroxisome proliferator-activated receptor gamma (PPARγ)* and *adipocyte protein 2 (AP2)* (see Additional file 1: Table 3 for primer sequences) was assessed as previously described [36]. Gene expression was performed with Power SYBR Green PCR Master Mix (Applied Biosystems, Warrington, Cheshire, UK) on an ABI Prism 7300 real-time PCR system (Thermo Fisher Scientific). The housekeeping gene *ribosomal phosphoprotein P0 (RPLP0)* was used as an internal control, and the relative expression of the studied genes was calculated using a mathematical model as previously described [37]. The expression levels of the inflammatory markers *interleukin 6 (IL-6)* and *tumor necrosis factor (TNF)* were analyzed with TaqMan Gene Expression Assays (Applied Biosystems) using an ABI Prism 7300 real-time PCR system (see Additional file 1: Table 4). The results were calculated using the delta Ct method using *glyceraldehyde-3-phosphate dehydrogenase (GAPDH)* as an endogenous control.

Chondrogenic differentiation

Chondrogenic differentiation was conducted at passage 5 or 6 as previously described (10,38) in micromass cultures. Briefly, 8 × 10⁴ ASCs were seeded into 24-well plate in a 10-μl volume and cells adhered for 3 h at 37 °C in a CO₂ incubator. Thereafter, ASCs were cultured in chondrogenic medium (CM, see Additional file 1: Table 1) for 14 days. After the chondrogenic differentiation, Alcian blue staining was performed as previously described [38].

Briefly, cell pellets were fixed with 4% PFA and stored in 70% ethanol. After fixing, pellets were dehydrated, embedded into paraffin, and sectioned at 4 μm thickness. The sections were rehydrated and stained with Alcian blue (pH 1.0) and counterstained with Nuclear Fast Red solution (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany). Samples were photographed using Zeiss Axio Vert.A1 microscope with Zeiss AxioCam MRC5.

Angiogenesis potential assay

For the angiogenesis potential assay, human umbilical vein endothelial cells (HUVECs) were isolated from the umbilical cord received from a planned cesarean section at the Department of Obstetrics and Gynecology, Tampere University Hospital, with donor consent. The study was conducted in accordance with the Ethics Committee of the Pirkanmaa Hospital District, Tampere (R13019). HUVEC isolation was performed as previously described [39]. HUVECs were cultured in endothelial medium (EM; Lonza) supplemented with 2% HS (BioWest, see Additional file 1: Table 1). For the angiogenesis potential assay, ASCs were plated in 48-well plates (Nunc) at a density of 23,000 cells/cm² at passage 4 or 6, and HUVECs were plated at a density of 4600 cells/cm² at passage 4 in EM after 3 h of attachment of ASCs. Cells were cocultured for 5 days and stained with 1:200 anti-collagen type IV (Domain, clone IV-4H12) mouse monoclonal antibody (Millipore) and goat anti-mouse IgG1 cross-adsorbed secondary antibody Alexa 488 (Thermo Fisher Scientific). Stained cells were photographed using Cell-IQ (CM Technologies Oy, Tampere, Finland) with a 10 × objective and 3 × 3 grid to detect vascular structures. Grids were stitched together with a Cell-IQ Analyzer (CM Technologies Oy), and quantitative analysis of angiogenesis was performed using AngioTool64 Version 0.6a (02.18.14) [40].

Immunogenicity

For immunogenicity and immunosuppression capacity studies, peripheral blood mononuclear cells (PBMCs) were isolated from buffy coat samples and frozen as previously described [8]. The buffy coat samples were obtained from the Finnish Red Cross Blood Service, and the study was conducted in accordance with the Declaration of Helsinki 1975, revised in Hong Kong 1989. The immunogenicity of ASCs was studied using a one-way mixed lymphocyte reaction (MLR) as previously described [8]. Briefly, irradiated ASCs at a density of 62,500 cells/cm² at passage 4 or 5 were cocultured with PBMCs at a density of 625,000 cells/cm² in 96-well plates (Nunc) for 5 days in HPL medium. For nonproliferative control samples, PBMCs were irradiated to prevent cell proliferation, and for proliferative control samples,

PBMCs were cultured with 10 µg/ml phytohemagglutinin-M (PHA; Sigma-Aldrich) to enhance proliferation. The proliferation of PBMCs was measured with BrdU ELISA (Roche Applied Science, Penzberg, Germany).

Immunosuppression capacity

The immunosuppressive capacity of ASCs was studied using two-way MLR in both direct and indirect cocultures as previously described [8]. Briefly, ASCs were pretreated with 10 ng/ml interferon-γ (Sigma-Aldrich) for 72 h to enhance the immunosuppressive capacity of ASCs. ASCs were plated in 24-well plates (Nunc) at a density of 63,000 c/cm² or in ThinCerts™-TC inserts (Greiner bio-one, Switzerland) at a density of 360,000 cells/cm² at passage 4, 5 or 6. A mixture of two PBMC donor cell lines was plated in wells at a density of 630,000 cells/cm². ASC and PBMC mixtures were also cultured alone as control samples. After 5 days of coculture in HPL medium, the proliferation of PBMCs was measured with the BrdU ELISA.

BrdU ELISA for lymphocyte proliferation

The proliferation of PBMCs was assessed with the BrdU ELISA 5 days after cells were plated in wells for immunogenicity and immunosuppression capacity studies according to the manufacturer's instructions. Calculations were performed from raw absorbance data of BrdU ELISA as previously described [8]. Briefly, average absorbance values were calculated for each group. The average absorbance of ASCs alone was subtracted from the MLR average values for each well. Thereafter, MLR values were divided by the average autologous PBMC value, which was considered the baseline response in one-way MLR, or MLR values were divided by the average PBMC mixture value without ASCs, which was considered the baseline response in two-way MLR. According to the performed calculations, in one-way MLR, a value of 1 indicates the baseline response, and values >1 indicate activation; in two-way MLR, a value of 1 represents a baseline response, and reaction values <1 indicate suppression. The performed calculations were modified from McIntosh et al. [41].

Statistical analyses

The differences in mineralization (QAR), relative expression of *ALP*, proinflammatory markers *IL-6* and *TNF*, adipogenic differentiation (large LD formation), angiogenic potential (vasculature area and length) and immunosuppression capacity in direct cocultures between leaner WD twins compared with heavier WD cotwins were assessed using multilevel mixed-effects regression models to account for the nested data structure (i.e., multiple measurements within twin and pairing of the

cotwins). To statistically test whether leaner and heavier WD cotwins differ in clinical parameters and surface marker expression of ASCs, the Wilcoxon signed-rank test was used. A *p* value less than 0.05 was considered significant. Data on clinical parameters and surface marker expression are presented as the median and the min and max values, and other data are presented as the mean ± standard deviation (SD). Statistical analyses were performed using Stata statistical software (Release 13.0, Stata Corporation, College Station, TX, USA), and graphs were generated using GraphPad Prism 5.02 (GraphPad Software, Inc.).

Results

Within WD twin pairs, heavier cotwins have more impaired metabolic health

As per design, the BMI of heavier WD cotwins was significantly higher than that of leaner WD twins (*p* = 0.0431). In four out of five WD twin pairs, heavier cotwins showed elevated levels of LDL, hs-CRP, and leptin and impaired insulin sensitivity measured as HOMA-IR compared with leaner cotwins. None of the donors satisfied the criteria for type 2 diabetes (Table 1). In addition, in four out of five WD twin pairs, the heavier cotwins showed lower levels of HDL, and all heavier WD twins showed significantly lower plasma adiponectin (*p* = 0.0431) than leaner WD cotwins (Table 1).

ASCs showed an MSC-like immunophenotype independent of weight difference, except for CD14 and CD146

ASCs showed a characteristic MSC-like surface marker expression profile and morphology. ASCs showed high median expression (>99%) of the surface markers CD73, CD90, CD105, and HLA-ABC (Table 2). The median expression of CD14, CD19, CD45RO, and HLA-DR was very low (≤2%), the median expression of CD34 was low (>2 to <7%), and the median expression of CD54 was moderate (>11 to <21%; Table 2). However, surface marker expression was similar between leaner and heavier WD twins, except for the expression of the surface markers CD14 and CD146, whose expression was significantly higher in all leaner twins than in heavier cotwins (*p* = 0.0394 and *p* = 0.0431, respectively, Table 2). The results of surface marker expression of ASCs isolated from each MZ twin donor are shown in Additional file 1: Table 5 and morphology in Additional file 7: Figure 6.

Acquired weight did not affect the proliferation of ASCs

The proliferation of ASCs was studied using a CCK-8 kit after 4, 7, and 11 days of culturing ASCs in HPL medium. Proliferation was similar between leaner and heavier WD

Table 2 Surface marker expression of ASCs isolated from MZ twin pairs at passage 5

Surface marker	Weight-discordant pairs ($\Delta\text{BMI} > 3 \text{ kg/m}^2$)						p Value
	Leaner cotwin			Heavier cotwin			
	Median	Min	Max	Median	Min	Max	
CD14	0.3	0.3	0.5	0.2	0.2	0.3	0.039
CD19	1.5	0.9	2.9	1.6	1.0	3.1	0.588
CD34	2.3	2.1	8.3	7.1	1.8	9.8	0.345
CD45RO	0.9	0.6	1.0	0.9	0.7	1.4	0.219
CD54	11.4	4.0	35.7	13.1	4.0	24.8	0.276
CD73	100	99.9	100	100	99.9	100	ND
CD90	99.7	96.6	100	99.7	99.7	100	0.090
CD105	99.3	99.1	99.7	99.2	95.1	99.7	0.276
CD146	45.0	5.2	71.3	14.5	5.0	33.8	0.043
HLA-DR	0.7	0.3	6.4	0.4	0.2	0.4	0.138
HLA-ABC	99.6	98.2	99.7	99.5	99.3	99.9	0.343

Wilcoxon's signed-rank test was used to compare values of the leaner vs the heavier cotwin. A P value less than 0.05 was considered significant (shown in bold). ND = not detected




Fig. 1 Proliferation of ASCs after 4, 7, and 11 days of culture in HPL medium. Leaner and heavier twin pairs show similar proliferation capacities. Data are presented as the average \pm SD

cotwins (Fig. 1), but more variability was seen between pairs (see Additional file 2: Fig. 1).

Osteogenic differentiation capacity of ASCs showed characteristic donor variation that was not dependent on acquired weight

The osteogenic capacity of ASCs was studied after 14 days of osteogenic differentiation. QALP analysis showed similar ALP activity with both leaner and heavier WD twins (Fig. 2c). However, the relative expression of ALP was higher in three out of four leaner WD twins than in heavier WD cotwins (see Additional file 3: Fig. 2e). In addition, the relative expression of RUNX2 showed similar expression in both leaner and heavier WD twins (Fig. 2d).


AR staining was performed after 21 days of osteogenic differentiation to study the late osteogenic differentiation capacity and mineralization of ASCs. AR staining showed the mineralization capacity of ASCs with all twin pairs

under osteogenic differentiation conditions (Additional file 3: Fig. 2a). A representative image of AR staining is shown in Fig. 2a. The mineralization capacity was lower in three out of four heavier WD twins than in the leaner WD cotwins (Fig. 2b). The osteogenic differentiation capacity results of ASCs isolated from each donor can be found in Additional file 3: Fig. 2.

ASCs from both leaner and heavier WD twins was able to differentiate toward chondrogenic lineage, as shown by Alcian blue staining (see Additional file 8: Fig. 7).

Heavier WD twin ASCs had significantly more large LD than ASCs isolated from leaner cotwins

The adipogenic capacity of ASCs was studied after 14 days of adipogenic differentiation. ORO staining showed that ASCs isolated from heavier WD twins had higher differentiation capacity toward the adipogenic lineage than ASCs isolated from leaner cotwins (Fig. 3a, see Additional file 4: Fig. 3a). A representative image of ORO staining is shown in Fig. 3a. QORO showed that ASC isolated from heavier WD twins had a significantly higher number of large LD than ASC isolated from leaner WD cotwins ($p = 0.011$, Fig. 3b). However, the relative expression of AP2 and PPAR γ after 14 days in adipogenic conditions showed similar gene expression between leaner and heavier WD twins (Fig. 3c,d), except for one twin pair in which the heavier cotwin showed higher expression of AP2 and PPAR γ (Additional file 4: Figure S3c,d). The adipogenic differentiation capacity results of each individual ASC donor are presented separately in Additional file 4: Fig. 3.



ASCs from leaner WD twins showed higher angiogenic potential



Collagen type IV staining of ASC and HUVEC cocultures showed that HUVECs formed vasculature-like structures with both leaner and heavier WD twins (Fig. 4a). The image analysis confirmed that leaner WD twins showed a 21% larger area ($p=0.039$, Fig. 4b) and 25% longer vasculature-like structures ($p=0.031$, Fig. 4c) than heavier cotwins. The vasculature area and length of the vasculature-like structures formed from each donor can be found in Additional file 5: Fig. 4.


ASCs showed low immunogenicity independent of intrapair weight differences; however, heavier WD donors showed superior immunosuppression capacity

The immunogenicity of ASCs was studied using one-way MLR, and the proliferation of PBMCs was measured after 5 days of coculturing ASCs with PBMCs. ASCs isolated from both WD leaner and heavier cotwins has low immunogenicity, which was assessed as low PBMC proliferation in cocultures with ASCs. PHA-stimulated

PBMCs represents a positive control (Fig. 5a). The immunogenicity results of each donor can be found in Additional file 6: Fig. 5a.

The immunosuppressive capacity of ASCs was studied using two-way MLR in both direct and indirect cocultures. The results showed that ASCs isolated from both leaner and heavier WD twins suppressed PBMC proliferation in direct two-way MLR (Fig. 5b). The immunosuppressive capacity of ASCs significantly differed within WD twin pairs in direct cocultures. In four out of five WD twin pairs, the heavier cotwins showed improved suppression capacity compared with the leaner cotwins ($p=0.017$, Fig. 5b). In indirect coculture, ASCs derived from both leaner and heavier WD twin donors did not suppress PBMC proliferation (Fig. 5c). Suppression of PBMC proliferation was more effective in direct culture than in indirect culture (Fig. 5b,c). Immunosuppression results of ASCs isolated from each donor can be found in Additional file 6: Fig. 5b, c.





Within WD twin pairs, ASCs from heavier cotwins showed significantly elevated expression of the inflammatory marker *TNF*

The relative expression of the inflammatory markers *IL-6* and *TNF* was analyzed in ASCs after 14 days of culture in HS medium. The relative expression of *IL-6* was slightly elevated in heavier WD twins than in leaner cotwins (Fig. 5d). However, the relative expression of *TNF* was significantly elevated compared with that in leaner WD cotwins ($p = 0.015$, Fig. 5e). The expression of inflammatory markers from each donor can be found in Additional file 6: Fig. 5d, e.

Discussion

To our knowledge, the current study is the first to investigate the effect of intrapair weight differences on ASC characteristics using rare MZ WD twin pairs with controls for genetic backgrounds. Our material consisted of 10 donors comprising five MZ WD twin pairs with intrapair weight differences ranging from 12 to 27 kg, which is exceptional for MZ pairs in general [42].

Several biochemical variables were measured from plasma samples of MZ twin pairs to characterize the current metabolic health of the donors. As expected, heavier WD cotwins had higher LDL, hs-CRP, insulin resistance, and leptin levels and lower HDL and adiponectin levels than leaner WD cotwins, as has been reported before for weight-discordant MZ pairs [30]. In general, all donors were clinically and even metabolically rather healthy independent of BMI status. As relatively young adults, even obese twins have not yet developed

clinical complications and therefore represent an ideal sample to study the effects of adiposity alone on ASC characteristics.

Previous studies have demonstrated that obesity alters ASC characteristics such as proliferation capacity [15]. Most of the studies have shown reduced proliferation capacity of obASCs compared with lnASCs [17, 19–21], although opposing results of elevated obASC proliferation have also been reported [16, 18]. Our results showed that the acquired weight of the donor compared to his/her leaner genetically matched cotwin does not affect the proliferation capacity of ASCs. Similar findings have been reported earlier by Mojallal et al. [43], who showed that BMI and proliferation did not significantly correlate. In the current study, the genetic and other shared backgrounds seemed to have a greater effect on proliferation capacity than intrapair weight difference, since proliferation rates varied greatly between pairs but were similar within pairs in both leaner and heavier WD cotwins.

Obesity has been shown to alter the immunophenotype of ASCs [16, 17]; specifically, higher expression of HLA II and CD106 and lower expression of CD29 have been observed in obASCs than in lnASCs [16]. De Girolamo et al. reported lower expression of CD54 and CD34 in obASCs than in lnASCs [17]. On the other hand, it has been reported that obesity of the donor does not affect the CD marker expression of ASCs [26, 44, 45]. In the current study, ASC from all donors showed a characteristic immunophenotype of MSCs.

Interestingly, in our study, the expression of CD146 was lower in ASCs from heavier twins than in ASCs from

leaner cotwins. CD146 is considered a marker for pericytes, which are localized around the endothelial layer in capillaries and are involved in angiogenesis and blood vessel homeostasis and functions [46]. Silva et al. [24] reported that stromal vascular fraction (SVF) cells from donors with obesity have higher expression of CD146 and therefore higher levels of pericytes in their SVF. Our results with culture-expanded ASCs are opposing, suggesting that heavier cotwins would have a decreased number of pericytes in their AT. Lower CD146 expression could indicate decreased proangiogenic potential of obASCs. In line with our hypothesis, it was previously reported that obASCs have reduced proangiogenic potential that is mediated by extracellular vesicles derived from obASCs [47]. To study the angiogenic potential of ASCs, we cocultured ASCs with HUVECs and analyzed the formed vascular-like structures. Our results revealed a significantly decreased angiogenic potential of heavier WD twins compared with leaner cotwins. Thus, the acquired weight of a donor has a significant influence on the angiogenic potential of ASCs, which was evidenced in our study as reduced expression of CD146 and impaired capacity to form vascular-like structures in coculture with HUVECs.

The effect of obesity on ASC differentiation capacity has been studied previously, but the results have been contradictory. The obesity of the donor has been shown to reduce the differentiation capacity of isolated ASC [16, 17, 19, 21, 23–25]. In most of the studies, elevated BMI has been linked to compromised osteogenesis [17, 19, 23] and adipogenesis [16, 17, 21, 24, 25]. Opposing results, however, exist where the differentiation capacity has increased [18, 26] or not been affected due to obesity of the donors [19, 27]. In our study, ASCs differentiated toward adipogenic lineages and showed characteristic biological donor variation in differentiation capacity. In addition, a significantly increased number of large lipid droplets formed in heavier cotwins compared with leaner cotwins, which indicates a more prominent adipogenic potential of donors with a higher BMI, as previously reported [18, 26]. Moreover, in a study by Zhu et al., it was shown that ASCs from obese pigs has increased adipogenic differentiation capacity, which was partly linked to upregulation of *TNF* [48]. This result was in line with our study, where ASCs from heavier cotwins had an increased number of large lipid droplets combined with higher expression of proinflammatory *IL-6* and *TNF*. Similarly, Serena et al. reported that obASCs showed higher expression of *TNF* than InASCs [28]. The increased expression of proinflammatory markers and improved adipogenic differentiation capacity of ASCs seem both to be associated with increased donor weight. It could be speculated that increased *TNF* expression in

obASCs may explain the increased adipogenic differentiation capacity of heavier WD cotwins in this study.

The effect of obesity on osteogenic differentiation capacity has shown varying results. A poor capacity of obASCs for osteogenic differentiation has previously been linked with the upregulation of inflammatory transcripts [21]. Furthermore, it has been shown that patients diagnosed with inflammatory diseases have a reduced capacity for osteogenesis and a higher incidence of osteoporosis [49]. In our study, the higher expression of proinflammatory markers did not lead to differences in osteogenic capacity, although three out of four heavier WD twins had reduced mineralization capacity and relative ALP expression compared with leaner WD cotwins. Our study is in line with a previous study showing that donor BMI does not significantly correlate with osteogenic differentiation capacity; however, a tendency for decreased expression of osteogenic markers can be observed [27].

The capacity of ASCs to modulate immune cells and immune responses has made them potential tools for the treatment of chronic inflammatory diseases [9]. In previous studies, obesity has been shown to impair the therapeutic value of ASCs and reduce the immunosuppressive capacity of ASCs by enhancing the proliferation of T cells [28, 29]. These previous studies indicate that ASCs derived from donors with obesity may not be suitable for cell-based therapies, especially for the treatment of autoimmune diseases or inflammatory diseases [29]. Our results contradict these previous observations. All ASCs from the donors, regardless of intrapair weight difference, had low immunogenicity and were capable of immunosuppression. Unexpectedly, heavier cotwins showed a slightly higher but statistically significant capacity for immunosuppression in direct cocultures than leaner cotwins.

In the human body, ASCs faces drastic changes in AT during the development of obesity. These include changes in AT composition, structure and function as well as an increased number of immune cells and proinflammatory cytokines leading to metabolic dysfunction [14]. The inflammatory milieu, hypoxia, and abnormal metabolites in obese AT impair the functions of ASCs, and as a consequence, they gradually become compromised in their regulatory and modulatory functions over time [14]. A relevant question is whether the inflammatory milieu in obese AT will cause permanent changes in ASCs and whether we can observe these changes in vitro after long cell expansion periods. We have previously shown that ASC characteristics, e.g., proliferation, differentiation capacity, and immunophenotype, are modulated by in vitro culture conditions [10]. We speculate that the inflammatory environment of the source AT may

affect ASC characteristics in the early phases of in vitro culture, but the effect may be lost in long-term culture.

There were certain limitations in this study. We had a low number of MZ WD twin pairs with small, but significant difference in their BMI. Due to small biopsy size, the expansion of one ASC donor cell line took a longer time compared with other cell lines. That particular ASC donor cell line did not differentiate into adipogenic or osteogenic lineages and detached repeatedly on angiogenesis potential assay reducing the number of donors in differentiation studies, suggesting that the quality of the starting material might have an effect on cell behavior.

In summary, in this study, we observed that the acquired weight of a heavier donor compared to a genetically matched leaner cotwin led to lower expression of the surface marker CD146, impaired angiogenic potential, improved adipogenic differentiation capacity, and higher expression of the proinflammatory marker *TNF*. Our results show that the acquired weight of a donor has a significant influence on ASC characteristics, although all donors were metabolically rather healthy. In addition, heavier donors showed improved suppression capacity compared with leaner donors, while ASC proliferation, osteogenic differentiation capacity, and immunogenicity were similar independent of intrapair weight differences. Our results demonstrate that acquired weight has an influence on certain ASC characteristics independent of predisposing genetics.

Conclusions

Our results suggest that the acquired weight of a donor may lead to impaired angiogenic potential and increased adipogenic potential of ASCs, independent of genetic background. Considering the clinical use of ASCs, a careful characterization and selection of donors should be carried out, since the weight of a donor may influence the clinical potential of ASCs.

Abbreviations

ASC: Adipose stromal/stem cells; MSC: Mesenchymal stromal/stem cells; ISCT: The International Society for Cellular Therapy; AT: Adipose tissue; obASC: ASC isolated from donors with obesity; InASC: ASC isolated from lean donors; WD: Weight-discordant; MZ: Monozygotic; BMI: Body mass index; hs-CRP: High-sensitivity C reactive protein; ELISA: Enzyme-linked immunosorbent assay; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; HOMA-IR: Insulin resistance index; HS: Human serum; HPL: Human platelet lysate; PE-Cy7: Phycoerythrin cyanine 7; APC: Allophycocyanin; BV711: Brilliant violet 711; FITC: Fluorescein isothiocyanate; CCK8: Cell counting kit-8; DPBS: Dulbecco's phosphate-buffered solution; OM: Osteogenic medium; AR: Alizarin red; QAR: Quantified alizarin red; ALP: Alkaline phosphatase; AM: Adipogenic medium; ORO: Oil Red O; QORO: Quantified Oil Red O; LD: Lipid droplet; RUNX2: Runt-related transcription factor 2; PPAR γ : Peroxisome proliferator activated receptor gamma; AP2: Adipocyte protein 2; RPLP0: Ribosomal protein P0; IL-6: Interleukin 6; TNF: Tumor necrosis factor; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; HUVEC: Human umbilical vein endothelial cells; EM: Endothelial medium; PBMC: Peripheral blood mononuclear cells; MLR: Mixed

lymphocyte reaction; PHA: Phytohemagglutinin-M; SD: Standard deviation; ND: Not detected; SVF: Stromal vascular fraction.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13287-021-02587-0>.

Additional file 1: Supplementary Tables. Supplementary Table 1.

Medium composition of HS medium (BM), HPL medium, adipogenic medium (AM), osteogenic medium (OM), chondrogenic medium (CM) and endothelial medium (EM). **Supplementary Table 2.** Antibodies of surface protein markers and manufacturers. **Supplementary Table 3.** Forward and reverse sequences, product size and accession numbers of osteogenic and adipogenic gene expression markers. **Supplementary Table 4.** Inflammatory gene expression markers. **Supplementary Table 5.** Surface marker expression of ASCs isolated from MZ twin donors. **Supplementary Table 6.** P-values and statistical tests used. **Supplementary Table 7.** P-values and statistical tests used in proliferation. **Supplementary Table 8.** P-values and statistical tests used in osteogenic and adipogenic differentiation capacity, control condition (BM) vs. differentiation condition (OM/AM). **Supplementary Table 9.** P-values and statistical tests used in immunogenicity, sample vs. control condition (PHA).

Additional file 2: Figure 1. Proliferation capacity of ASCs. Pair numbers 1–5. All quantitative data are presented as the mean \pm SD.

Additional file 3: Figure 2. Osteogenic differentiation capacity of ASCs. (a) Alizarin red (AR) staining, (b) quantified AR staining, (c) alkaline phosphatase (ALP) activity, (d) relative expression of *RUNX2* and (e) *ALP*. Pair number 2–5. All quantitative data are presented as the mean \pm SD.

Additional file 4: Figure 3. Adipogenic differentiation capacity of ASCs. (a) Oil Red O (ORO) staining, (b) quantified ORO, (c) relative expression of *AP2* and (d) *PPAR γ* . Pair numbers 2–5. All quantitative data are presented as the mean \pm SD.

Additional file 5: Figure 4. (a) Vasculature area and (b) length of vasculature-like structures created by HUVEC in coculture with ASCs. Pair numbers 2–5. All quantitative data are presented as mean \pm SD.

Additional file 6: Figure 5. (a) Immunogenicity, immunosuppression capacity in (b) direct and (c) indirect cocultures, relative gene expression of (d) *IL-6* and (e) *TNF*. Pair numbers 1–5. PHA = Phytohemagglutinin-M. All quantitative data are presented as the mean \pm SD.

Additional file 7: Figure 6. Morphology of ASCs derived from MZ twin pairs. Inset = scale bar 100 μ m, larger picture = scale bar 1 mm.

Additional file 8: Figure 7. Chondrogenic differentiation capacity of ASCs derived from MZ twin pairs. Alcian blue staining, scale bar 100 μ m.

Acknowledgements

The authors thank Ms. Anna-Majja Honkala and Ms. Sari Kalliokoski for excellent technical assistance. We thank the Tampere Imaging Facility, Outi Paloheimo, Juha Heikkilä and Tarja Toimela for technical assistance in the angiogenesis potential assays. We thank Antti Aula for technical assistance in the cell irradiation.

Authors' contributions

MJ was involved in conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript. SH performed collection and assembly of data, data analysis and interpretation, and final approval of manuscript. HH contributed to data analysis and interpretation and final approval of manuscript. AR, KK and JK done provision of study material or patients and final approval of manuscript. KHP was performed in provision of study material or patients, data analysis and interpretation, and the final approval of manuscript. SM contributed to conception and design, financial support, administrative support, provision of study material or patients, data analysis and interpretation, final approval of manuscript. MP performed conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by Business Finland and the Academy of Finland (Grant Nos. 326588 to SM and 311084 to MP), the Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital, the Finnish Cultural Foundation (Grant No. 00190409 to MJ) and the Tampere University Graduate School for Medicine and Life Sciences (MJ). SH was supported by Helsinki University Hospital funds, the Finnish Diabetes Research Foundation, the Orion Foundation, the Paulo Foundation, the Finnish Medical Foundation and the Maud Kuistila Foundation. KHP was supported by the Academy of Finland (Grant Nos. 272376, 314383, and 266286), the Finnish Medical Foundation, the Gyllenberg Foundation, the Finnish Diabetes Research Foundation, the Sigrid Juselius Foundation, the Novo Nordisk Foundation (NNF170C0027232 and NNF100C1013354), the University of Helsinki and the Government Research Funds through Helsinki University Hospital. JK was supported by the Academy of Finland Centre of Excellence in Complex Disease Genetics (Grant 312073).

Availability of data and materials

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The MZ twin study was conducted in accordance with the Ethics Committee of Hospital District of Helsinki and Uusimaa, Helsinki, Finland (270/13/03/01/2008), and HUVEC collection for angiogenesis potential assay was conducted in accordance with the Ethics Committee of the Pirkanmaa Hospital District, Tampere (R13019). Written informed consent was obtained from all participants and donors.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Adult Stem Cell Group, Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, 33014 Tampere, Finland. ²Research, Development and Innovation Centre, Tampere University Hospital, Tampere, Finland. ³Obesity Research Unit, Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland. ⁴Obesity Center, Abdominal Center, Endocrinology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. ⁵Faculty of Social Sciences, University of Tampere, Tampere, Finland. ⁶Institute for Molecular Medicine FIMM, HiLIFE, University of Helsinki, Helsinki, Finland. ⁷Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland.

Received: 23 March 2021 Accepted: 11 September 2021

Published online: 26 September 2021

References

- Patrikoski M, Mannerström B, Miettinen S. Perspectives for clinical translation of adipose stromal/stem cells. *Stem Cells Int*. 2019;2019:5858247.
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006;8(4):315–7.
- Alt EU, Senst C, Murthy SN, Slakey DP, Dupin CL, Chaffin AE, et al. Aging alters tissue resident mesenchymal stem cell properties. *Stem Cell Res*. 2012;8(2):215–25.
- Choudhery MS, Badowski M, Muise A, Pierce J, Harris DT. Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation. *J Transl Med*. 2014;12:8.
- de Girolamo L, Lopa S, Arrigoni E, Sartori MF, Baruffaldi Preis FW, Brini AT. Human adipose-derived stem cells isolated from young and elderly women: their differentiation potential and scaffold interaction during in vitro osteoblastic differentiation. *Cytotherapy*. 2009;11(6):793–803.
- Aksu AE, Rubin JP, Dudas JR, Marra KG. Role of gender and anatomical region on induction of osteogenic differentiation of human adipose-derived stem cells. *Ann Plast Surg*. 2008;60(3):306–22.
- Van Harmelen V, Röhrig K, Hauner H. Comparison of proliferation and differentiation capacity of human adipocyte precursor cells from the omental and subcutaneous adipose tissue depot of obese subjects. *Metab Clin Exp*. 2004;53(5):632–7.
- Patrikoski M, Sivula J, Huhtala H, Helminen M, Salo F, Mannerström B, et al. Different culture conditions modulate the immunological properties of adipose stem cells. *Stem Cells Transl Med*. 2014;3(10):1220–30.
- McIntosh K, Zvonick S, Garrett S, Mitchell JB, Floyd ZE, Hammill L, et al. The immunogenicity of human adipose-derived cells: temporal changes in vitro. *Stem Cells*. 2006;24(5):1246–53.
- Patrikoski M, Juntunen M, Boucher S, Campbell A, Vemuri MC, Mannerström B, et al. Development of fully defined xeno-free culture system for the preparation and propagation of cell therapy-compliant human adipose stem cells. *Stem Cell Res Ther*. 2013;4(2):27.
- WHO. Obesity and overweight (2020) <https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight>. Accessed Jun 1 2020
- Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol*. 2011;11(2):85–97.
- Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. *BMC Public Health*. 2009;9:88.
- Louwen F, Ritter A, Kreis NN, Yuan J. Insight into the development of obesity: functional alterations of adipose-derived mesenchymal stem cells. *Obes Rev*. 2018;19(7):888–904.
- Vyas KS, Bole M, Vasconez HC, Banuelos JM, Martinez-Jorge J, Tran N, et al. Profile of adipose-derived stem cells in obese and lean environments. *Aesthet Plast Surg*. 2019;43(6):1635–45.
- Pachón-Peña G, Serena C, Ejarque M, Petriz J, Duran X, Oliva-Olivera W, et al. Obesity determines the immunophenotypic profile and functional characteristics of human mesenchymal stem cells from adipose tissue. *Stem Cells Transl Med*. 2016;5(4):464–75.
- De Girolamo L, Stanco D, Salvatori L, Coroniti G, Arrigoni E, Silecchia G, et al. Stemness and osteogenic and adipogenic potential are differently impaired in subcutaneous and visceral adipose derived stem cells (ASCs) isolated from obese donors. *Int J Immunopathol Pharmacol*. 2013;26(1 Suppl):11–21.
- Mitterberger MC, Mattesich M, Zwerschke W. Bariatric surgery and diet-induced long-term caloric restriction protect subcutaneous adipose-derived stromal/progenitor cells and prolong their life span in formerly obese humans. *Exp Gerontol*. 2014;56:106–13.
- Frazier TP, Gimble JM, Devay JW, Tucker HA, Chiu ES, Rowan BG. Body mass index affects proliferation and osteogenic differentiation of human subcutaneous adipose tissue-derived stem cells. *BMC Cell Biol*. 2013;14:34.
- Pérez LM, Bernal A, de Lucas B, San Martín N, Mastrangelo A, García A, et al. Altered metabolic and stemness capacity of adipose tissue-derived stem cells from obese mouse and human. *PLoS ONE*. 2015;10(4):e0123397.
- Oñate B, Vilahur G, Ferrer-Lorente R, Ybarra J, Díez-Caballero A, Ballesta-López C, et al. The subcutaneous adipose tissue reservoir of functionally active stem cells is reduced in obese patients. *FASEB J*. 2012;26(10):4327–36.
- Conley SM, Hickson LJ, Kellogg TA, McKenzie T, Heimbach JK, Taner T, et al. Human obesity induces dysfunction and early senescence in adipose tissue-derived mesenchymal stromal/stem cells. *Front Cell Dev Biol*. 2020;8:197.
- Strong AL, Hunter RS, Jones RB, Bowles AC, Dutreil MF, Gaupp D, et al. Obesity inhibits the osteogenic differentiation of human adipose-derived stem cells. *J Transl Med*. 2016;14:27.
- Silva KR, Liechocki S, Carneiro JR, Claudio-da-Silva C, Maya-Monteiro CM, Borojevic R, et al. Stromal-vascular fraction content and adipose stem cell behavior are altered in morbid obese and post bariatric surgery ex-obese women. *Stem Cell Res Ther*. 2015;6:72.
- Pérez LM, de Lucas B, Lunyak VV, Gálvez BG. Adipose stem cells from obese patients show specific differences in the metabolic regulators vitamin D and Gas5. *Mol Genet Metab Rep*. 2017;12(C):51–6.

26. Yang HJ, Kim K, Kim MK, Lee SJ, Ryu YH, Seo BF, et al. The stem cell potential and multipotency of human adipose tissue-derived stem cells vary by cell donor and are different from those of other types of stem cells. *Cells Tissues Organs* (Print). 2014;199(5–6):373–83.
27. Oliva-Olivera W, Leiva Gea A, Lhamyani S, Coín-Aragüez L, Alcaide Torres J, Bernal-López MR, et al. Differences in the osteogenic differentiation capacity of omental adipose-derived stem cells in obese patients with and without metabolic syndrome. *Endocrinology*. 2015;156(12):4492–501.
28. Serena C, Keiran N, Ceperuelo-Mallafre V, Ejarque M, Fradera R, Roche K, et al. Obesity and type 2 diabetes alters the immune properties of human adipose derived stem cells. *Stem Cells*. 2016;34(10):2559–73.
29. Strong AL, Bowles AC, Wise RM, Morand JP, Dutreil MF, Gimble JM, et al. Human adipose stromal/stem cells from obese donors show reduced efficacy in halting disease progression in the experimental autoimmune encephalomyelitis model of multiple sclerosis. *Stem Cells*. 2016;34(3):614–26.
30. Heinonen S, Muniandy M, Buzkova J, Mardinoglu A, Rodríguez A, Frühbeck G, et al. Mitochondria-related transcriptional signature is down-regulated in adipocytes in obesity: a study of young healthy MZ twins. *Diabetologia*. 2017;60(1):169–81.
31. Pietiläinen KH, Rissanen A, Laamanen M, Lindholm A, Markkula H, Yki-Järvinen H, et al. Growth patterns in young adult monozygotic twin pairs discordant and concordant for obesity. *Twin Res*. 2004;7(5):421–9.
32. Lindroos B, Boucher S, Chase L, Kuokkanen H, Huhtala H, Haataja R, et al. Serum-free, xeno-free culture media maintain the proliferation rate and multipotentiality of adipose stem cells in vitro. *Cytotherapy*. 2009;11(7):958–72.
33. Patrikoski M, Lee MHC, Mäkinen L, Ang XM, Mannerström B, Raghunath M, et al. Effects of macromolecular crowding on human adipose stem cell culture in fetal bovine serum, human serum, and defined xeno-free/serum-free conditions. *Stem Cells Int*. 2017;2017:6909163.
34. Ojansivu M, Vanhatupa S, Björkvik L, Häkkinen H, Kellomäki M, Autio R, et al. Bioactive glass ions as strong enhancers of osteogenic differentiation in human adipose stem cells. *Acta Biomater*. 2015;21:190–203.
35. Hyvari L, Ojansivu M, Juntunen M, Kartasalo K, Miettinen S, Vanhatupa S. Focal adhesion kinase and ROCK signaling are switch-like regulators of human adipose stem cell differentiation towards osteogenic and adipogenic lineages. *Stem Cells Int*. 2018;12(2018):2190657.
36. Vanhatupa S, Ojansivu M, Autio R, Juntunen M, Miettinen S. Bone morphogenetic protein-2 induces donor-dependent osteogenic and adipogenic differentiation in human adipose stem cells. *Stem Cells Transl Med*. 2015;4(12):1391–402.
37. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res*. 2001;29(9):e45.
38. Mäenpää K, Ellä V, Mauno J, Kellomäki M, Suuronen R, Ylikomi T, et al. Use of adipose stem cells and polylactide discs for tissue engineering of the temporomandibular joint disc. *J R Soc Interface*. 2010;7(42):177–88.
39. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins Identification by morphologic and immunologic criteria. *J Clin Invest*. 1973;52(11):2745–56.
40. Zudaire E, Gambardella L, Kurcz C, Vermeren S. A computational tool for quantitative analysis of vascular networks. *PLoS ONE*. 2011;6(11):e27385.
41. McIntosh KR. Evaluation of cellular and humoral immune responses to allogeneic adipose-derived stem/stromal cells. *Methods Mol Biol*. 2011;702:133–50.
42. Silventoinen K, Jelenkovic A, Sund R, Yokoyama Y, Hur Y, Cozen W, et al. Differences in genetic and environmental variation in adult BMI by sex, age, time period, and region: an individual-based pooled analysis of 40 twin cohorts. *Am J Clin Nutr*. 2017;106(2):457–66.
43. Mojallal A, Lequeux C, Shipkov C, Duclos A, Braye F, Rohrich R, et al. Influence of age and body mass index on the yield and proliferation capacity of adipose-derived stem cells. *Aesthet Plast Surg*. 2011;35(6):1097–105.
44. Li M, Li X, Zhao L, Zhou J, Cheng Y, Wang J, et al. Human omental adipose-derived stem cells from donors with different body mass index had similar effects on proliferation and migration of endometrial cancer cells in vitro. *J Obstet Gynaecol Res*. 2019;45(2):417–27.
45. Oñate B, Vilahur G, Camino-López S, Díez-Caballero A, Ballesta-López C, Ybarra J, et al. Stem cells isolated from adipose tissue of obese patients show changes in their transcriptomic profile that indicate loss in stemcellness and increased commitment to an adipocyte-like phenotype. *BMC Genomics*. 2013;14:625.
46. Esteves CL, Donadeu FX. Pericytes and their potential in regenerative medicine across species. *Cytometry A*. 2018;93(1):50–9.
47. Togliatto G, Dentelli P, Gili M, Gallo S, Deregibus C, Biglieri E, et al. Obesity reduces the pro-angiogenic potential of adipose tissue stem cell-derived extracellular vesicles (EVs) by impairing miR-126 content: impact on clinical applications. *Int J Obes (Lond)*. 2016;40(1):102–11.
48. Zhu X, Ma S, Eirin A, Woollard JR, Hickson LJ, Sun D, et al. Functional plasticity of adipose-derived stromal cells during development of obesity. *Stem Cells Transl Med*. 2016;5(7):893–900.
49. Mundy GR. Osteoporosis and inflammation. *Nutr Rev*. 2007;65(12 Pt 2):147.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

